Norbert Bischofberger, Kronos Bio CEO
January 9, 2023 07:00 AM ESTUpdated 08:07 AM
Deals
R&D

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

Drew Armstrong

Executive Editor

Kro­nos Bio and Roche’s Genen­tech an­nounced a drug dis­cov­ery deal to hunt for and de­vel­op small mol­e­cule drugs aimed at tran­scrip­tion fac­tors that can dri­ve …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

J&J takes 340B fight with fed­er­al gov­ern­ment to court

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times